The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities

被引:51
|
作者
Conti, Rena M. [1 ,2 ]
Bach, Peter B. [3 ]
机构
[1] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA
[3] Mem Sloan Kettering Canc Ctr, Ctr Hlth Policy & Outcomes, New York, NY 10021 USA
关键词
PHYSICIAN RELATIONS; COST; INTEGRATION;
D O I
10.1377/hlthaff.2014.0540
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The federal 340B program gives participating hospitals and other medical providers deep discounts on outpatient drugs. Named for a section of the Veterans Health Care Act of 1992, the program's original intent was to help low-income and uninsured patients. But the program has come under scrutiny by critics who contend that some hospitals exploit the drug discounts to generate profits instead of either investing in programs for the poor or passing the discounts along to patients and insurers. We examined whether the program is expanding in ways that could maximize hospitals' ability to generate profits from the 340B drug discounts. We matched data for 960 hospitals and 3,964 affiliated clinics registered with the 340B program in 2012 with the socioeconomic characteristics of their communities from the US Census Bureau's American Community Survey. We found that hospital-affiliated clinics that registered for the 340B program in 2004 or later served communities that were wealthier and had higher rates of health insurance compared to communities served by hospitals and clinics that registered for the program before 2004. Our findings support the criticism that the 340B program is being converted from one that serves vulnerable patient populations to one that enriches hospitals and their affiliated clinics.
引用
收藏
页码:1786 / 1792
页数:7
相关论文
共 50 条
  • [1] Value of the 340B Drug Discount Program
    Kantarjian, Hagop
    Chapman, Robert
    JAMA ONCOLOGY, 2015, 1 (08) : 1029 - 1030
  • [2] Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016
    Conti, Rena M.
    Nikpay, Sayeh S.
    Buntin, Melinda B.
    JAMA NETWORK OPEN, 2019, 2 (10)
  • [3] 340B Drug Discount Program in the Cross Hairs
    Wood, William W.
    Weingart, Wendy
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2014, 6 (05) : 204 - 207
  • [4] Cost Consequences of the 340B Drug Discount Program
    Conti, Rena M.
    Bach, Peter B.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (19): : 1995 - 1996
  • [5] The Reach of the 340B Drug Pricing Program
    Albrecht, Joerg
    Mudahar, Sukhraj
    JAMA DERMATOLOGY, 2015, 151 (09) : 923 - 924
  • [6] Examining the Benefits of the 340b Drug Discount Program
    Gerlach, Jarrett
    McSweeney, Sarah
    Swearingen, Angela
    Coustasse, Alberto
    HEALTH CARE MANAGER, 2018, 37 (03) : 225 - 231
  • [7] Specialty Drug Price Trends in the Federal 340B Drug Discount Program
    Lee, Cho-Han
    Chang, Jerry
    McCombs, Jeffery
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (02): : 178 - +
  • [8] The 340b Drug Discount Program: Oncology's Optical Illusion
    Eagle, David
    Buell, Roberta L.
    Vacirca, Jeffrey
    ONCOLOGY-NEW YORK, 2013, 27 (11): : 1068 - +
  • [9] EVALUATION OF DRUG PRICE TRENDING IN THE FEDERAL 340B DRUG DISCOUNT PROGRAM
    Lee, C.
    McCombs, J.
    Stone, B.
    Chang, J.
    VALUE IN HEALTH, 2017, 20 (05) : A126 - A126
  • [10] Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program
    Zeta, Lowell M.
    FOOD AND DRUG LAW JOURNAL, 2015, 70 (04) : 481 - +